Business Wire

Study Investigates the Impact of Automating Respiration Rate Measurement Using Masimo Rad-G™ with RRp®

Share

Masimo (NASDAQ: MASI) today announced the results of a prospective, observational study published in Acta Paediatrica in which researchers from the Hospital for Sick Children in Toronto evaluated the accuracy of plethysmographic respiration rate measurement (RRp®) using Masimo Rad-G™, a rugged, handheld device, on malnourished, hospitalized children in Nigeria.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210328005012/en/

Masimo Rad-G™ with RRp® (Photo: Business Wire)

Masimo Rad-G™ with RRp® (Photo: Business Wire)

Noting that in resource-limited environments, respiration rate (RR) measurement is often used to directly inform medical decisions for children with respiratory problems, but that manual RR counting “remains a challenge,” Dr. Nancy Dale and colleagues investigated whether a technological solution might provide a useful alternative to manual counting. To make the evaluation, the researchers compared simultaneous device measurements and nurse-measured manual RR counts on malnourished children. The device chosen was the Masimo Rad-G, which uses a pulse oximetry sensor to measure both oxygen saturation and RRp, and which has been shown to provide good agreement between RRp and pediatrician-measured RR.2 They enrolled 514 children, aged 6 to 59 months, who were hospitalized between July 2019 and May 2020, in Borno State, Nigeria. Study nurses were trained to operate Rad-G and also perform manual RR counts as part of twice-daily patient assessment. RR was manually counted for 60 seconds while Rad-G simultaneously measured RRp via a sensor attached to the patient’s toe, and both measurements were recorded.

Analyzing the 6,889 paired RR measurements, the researchers found that the mean Rad-G RRp reading was 1.3 bpm (95% confidence interval 1.2 – 1.4 bpm) higher than the mean manual RR value. The mean absolute difference between the two methods was 4.4 bpm (95% CI 4.3 – 4.5 bpm). When RR was classified as either “normal” or “fast” breathing (using WHO pneumonia thresholds), the two methods resulted in the same classification 84% of the time. When RR was classified according to BedsidePEWS RR sub-scoring (a 4-point scale), 80% of the scores were the same, and 99.3% were within 1 point.

The researchers concluded that their findings “highlight the potential clinical impact of changing practice from manual to automated RR count. Clinical implementation of the device should be carefully monitored to measure impact on patient outcomes.”

Study co-author Dr. Stanley Zlotkin commented, “Technical solutions to improve clinical care are laudable. We look forward to continuing this research.”

RRp is one of multiple RR monitoring modalities offered by Masimo, which also include acoustic respiration rate (RRa®) and NomoLine® capnography (RRc™), helping clinicians ensure they have the most suitable tool for each patient scenario.

First developed in partnership with The Bill & Melinda Gates Foundation, Rad-G is a rugged, handheld device that provides clinically proven Masimo SET® pulse oximetry, respiration rate (RRp), and other important parameters. With its long-lasting rechargeable battery, robust rubber casing, and light weight, Rad-G makes it easier for clinicians to quickly assess patients and make informed care decisions anywhere pulse oximetry or vital signs checking is needed in a compact, portable form factor. Coupled with the universal Mini-Clip™ pulse oximeter sensor to provide the ultimate in handheld versatility, Rad-G can be used in a variety of settings, including limited-resource environments, both indoors and in the field.

In the U.S., RRp is 510(k) cleared for patients greater than two years old.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,10 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.11 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Dale N, Parshuram C, Tomlinson G, Shepherd S, Ashir GM, Maryah LB, Zlotkin S. Performance of automated versus nurse-measured respiratory rate measurements in hospitalized malnourished children. Acta Paediatr 2021. DOI: https://doi.org/10.1111/apa.15781.
  2. Alwadhi V, Sarin E, Kuma P et al. Measuring accuracy of plethysmography based respiratory rate measurement using pulse oximeter at a tertiary hospital in India. Pneumonia 2020;12:4. DOI: https://doi.org/10.1186/s41479-020-00067-2.
  3. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  4. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  5. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  6. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  7. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  8. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  9. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  10. Estimate: Masimo data on file.
  11. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of RRp®, Rad-G™, and SET®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including RRp, Rad-G, and SET®, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rockwell Automation and Comau Partner to Simplify Robot Integration for Manufacturers20.4.2021 10:30:00 EEST | Press release

Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, and Comau, a global leader in industrial automation and robot manufacturer, announced today that they are joining forces to give businesses worldwide vital tools to maximize manufacturing efficiencies through unified robot control solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005326/en/ Comau Rebel-S (Photo: Business Wire) “Industrial companies are looking for efficient ways to integrate robotics into their operations for process optimization and agility,” said Rockwell Automation Chairman and CEO Blake Moret. “Rockwell Automation’s collaboration with Comau will simplify programming and lifecycle management, accelerating time to value for our customers.” Moret said this expansion of robotic applications is rooted in Rockwell’s broader strategy to help industrial companies save ti

iProov Face Verification Selected by itsme® to Support Global Expansion20.4.2021 08:00:00 EEST | Press release

British company iProov has today announced that European digital identity leader, itsme®, has selected iProov’s Genuine Presence Assurance® technology to support its global expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419006005/en/ iProov's Genuine Presence Assurance® technology enables enterprises to securely verify the identity of customers online. (Photo: Business Wire) Launched in 2017 by qualified trust service provider, Belgian Mobile ID, itsme® is Belgium's digital identity app. It is currently used by more than 35% of the Belgian population and is relied on by more than 150 companies in the private sector (banks, insurance companies etc) and by the Belgian government. From now, users in the Netherlands will also have access to itsme®’s trusted ID solution and will be able to securely authenticate themselves and onboard to digital services. iProov will verify the faces of new users, whatever their mobi

Sale of 60.5% of ENGIE EPS by ENGIE to TCC: ENGIE EPS to Become NHOA20.4.2021 08:00:00 EEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005984/en/ (Photo: Business Wire) ENGIE has announced the signing of a Sale Purchase Agreement with Taiwanese company TCC for its 60.5% stake in the share capital of ENGIE EPS (Paris:EPS). TCC, with an over $10 billion market capitalization, is one of the pre-eminent industrial groups in Asia, with activities in battery manufacturing, cement production, power generation, environmental services, chemicals, logistics and infrastructures. TCC has been very active in recent years in developing renewable energy and energy storage systems. The completion of the transaction, executed at Euro 17.10 per share, corresponding to an aggregate consideration of Euro 132 million and an implied Enterprise Value of over Euro 240 million, will be followed, in accordance with applicable regulations, by the filing of an all-cash simplified mandatory tender offer for all outst

Beeline Russia and P.I. Works Expand Partnership Scope with Automated Radio Access Network Planning20.4.2021 08:00:00 EEST | Press release

Beeline, Russia’s established mobile operator, has partnered with P.I. Works on network planning project, aimed at streamlining the operator’s investment planning processes and revolutionizing customer experience. As a part of the project, P.I. Works SmartPlan, the cutting-edge automated and AI driven network planning solution, will be deployed nationwide. Prior to this agreement, P.I. Works provided network planning services for Beeline, which exemplified the SmartPlan’s Return on Investment and Service Quality based planning capabilities. This initial project covered three of Russia’s branches, Moscow, Krasnodar and Novosibirsk, and optimized investments by 19% for high-level technical calculations and resulted in a reduction of 23% of the number of planned sites with LTE extensions. These results highlight the investments that Beeline Russia is making in data networks, and supports the possibility of improving time-to-market, thereby paving the way to a nationwide full-scale automat

LG Chem to Accelerate the Advancement Into the Promising Carbon Nanotubes Market20.4.2021 08:00:00 EEST | Press release

LG Chem (KRX: 051910) has launched the largest Carbon Nanotube (CNT) manufacturing plant in Korea. The company is actively targeting the rapidly growing CNT market, widely used as the material for cathodes in electric vehicle batteries. On April 14th, LG Chem announced that the 1,200 metric tons (MT) expansion of Yeosu CNT 2nd Plant was completed and has begun the commercial operations. Combined with the existing 500 MT which started its first operation in 2017, LG Chem has obtained a total capacity of 1,700 MT. LG Chem’s new CNT 2nd Plant was constructed as the world’s largest single-line production facility with a self-developed fluidized bed reactor. The plant has achieved stable quality control by complete automation and reduced power consumption by 30% through process innovation. The CNT produced at this plant will be supplied to market-leading global electric vehicle battery companies as a conductive additive. Also, its applications will be extended to a wide range of fields such

Xsolla Introduces Safe and Secure Solution to Manage Worldwide Influencer Payouts for Developers of All Sizes19.4.2021 17:00:00 EEST | Press release

Xsolla, the video game commerce company powered by Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, today introduced its Influencer Payouts solution that allows developers to easily manage safe and secure payouts to influencers who promote their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005313/en/ Learn how Influencer Payouts can work for you. (Graphic: Business Wire) Xsolla’s new Influencer Payouts solution empowers developers from indie to enterprise-level with a convenient and efficient tool that can automate performance-based payments to content creators utilizing a tiered structure that can quickly be customized and scaled to reach influencers at all levels around the world. Developers can choose from multiple options for influencers, such as revenue sharing based on the number of views, direct sales, or the number of hour

VELO3D Adds Renowned Business Leader Stefan Krause to Board of Directors as Audit Committee Chair19.4.2021 16:04:00 EEST | Press release

VELO3D Inc., a leader in additive manufacturing (AM) for high-value metal parts, today announced the appointment of renowned business leader Stefan Krause to the company’s board of directors as audit committee chair. With more than 30 years of experience working at some of the most recognizable and successful companies in the world, Krause has built a singular career that previously included a chief financial officer (CFO) role at BMW – where he was the youngest ever to hold the position and a member of the management board. Krause then took on a similar role at Deutsche Bank, earning himself a reputation as one of the world’s top CFOs. He also previously served as chairman of Rolls Royce Motorcars, Postbank AG and BHF Bank. He has been in the supervisory boards of Rocket Internet and Allianz AG. Krause has also been involved with multiple startups during his career and has been CEO and co-founder of electric vehicle maker Canoo. “Stefan’s international business background, his experti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom